Biologics manufacturing, which produces monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapy products through biological processes that differ fundamentally from chemical synthesis, has historically relied on batch and fed-batch manufacturing modes in which a bioreactor is charged with cells and nutrients, run to completion over a defined cycle, and then harvested and cleaned before the next batch begins. Continuous bioprocessing, which runs the upstream cell culture and downstream purification stages as integrated flowing processes without discrete batch cycles, offers theoretical advantages in productivity, consistency, and capital efficiency that have driven sustained research and development investment by biopharmaceutical manufacturers and equipment suppliers. The transition from batch to continuous processing is now progressing from pilot demonstrations and regulatory submissions toward commercial-scale implementation at multiple biopharmaceutical manufacturers, representing one of the more significant operational transformations in the history of industrial biologics manufacturing.
Perfusion Bioreactors and Upstream Continuous Processing
The upstream component of continuous bioprocessing involves maintaining cell cultures in a steady-state condition at high cell density by continuously adding fresh medium and removing spent medium and product while retaining the cells in the bioreactor. This perfusion operating mode differs from fed-batch culture, in which nutrients are added periodically but the culture volume and cell population are not at steady state, by achieving a constant cellular environment that can support higher viable cell densities and more consistent protein expression over extended operating periods. Perfusion bioreactor operation requires cell retention devices, typically alternating tangential flow filtration or acoustic separation systems, that separate cells from the harvested culture fluid with sufficient efficiency to maintain the cell density and culture viability required for sustained high-productivity operation.
The productivity advantage of perfusion over fed-batch is not universal and depends on the specific cell line, product molecule, and production context. For high-expression cell lines producing stable monoclonal antibodies, fed-batch processes have achieved product titres that make the productivity case for perfusion less compelling than it was in the lower-titre era of biologics manufacturing. For cell lines producing unstable or glycosylation-sensitive molecules that benefit from minimal residence time in the bioreactor, perfusion provides a quality advantage by allowing product harvest and immediate stabilisation before degradation or modification can occur. The continuous manufacturing case is therefore strongest for specific product types and manufacturing contexts rather than as a universal replacement for all fed-batch biologics production.
Sartorius, Cytiva (formerly GE Healthcare Life Sciences), and Merck KGaA's MilliporeSigma are the primary suppliers of perfusion bioreactors and cell retention systems to biopharmaceutical manufacturers, with each offering integrated hardware and consumables for perfusion operation at scales from development bench to commercial production. The integration of bioreactor control systems with perfusion operation requires process analytical technology (PAT) tools that monitor culture state variables in real time to maintain the steady-state conditions required for reproducible continuous operation, and the PAT capability of modern bioprocess control platforms has been a critical enabler of the operational consistency that regulatory submissions for continuous processes require.
Downstream Continuous Processing Challenges
The downstream purification of biologics, encompassing the sequential chromatography, filtration, and viral inactivation steps that remove process and product-related impurities to achieve the purity and safety specifications of biopharmaceutical products, has been slower to adopt continuous operation than the upstream bioreactor step. The technical challenge of running chromatography as a continuous process, rather than the standard column loading, washing, and elution cycles that characterise batch downstream processing, has been addressed by multicolumn chromatography systems that cycle multiple columns through sequential stages of a chromatography operation, maintaining continuous product flow while each individual column goes through its batch-like loading and regeneration cycle.
Novatek International's MCSGP (Multicolumn Countercurrent Solvent Gradient Purification), Cytiva's BioSMB continuous chromatography platform, and Pall Corporation's continuous downstream systems represent the commercial implementation of continuous chromatography for biologics purification. These systems have been validated in regulatory submissions and are in commercial use at multiple biopharmaceutical manufacturers for specific purification steps, most commonly protein A capture chromatography for monoclonal antibody purification where the high resin cost and high product concentration make productivity improvements from continuous operation particularly valuable.
Viral inactivation, a critical safety step in biologics manufacturing that uses low pH treatment to inactivate lipid-enveloped viruses, presents a specific challenge for continuous processing because the standard batch low pH hold requires a defined residence time to ensure complete inactivation across the entire product lot. Continuous tubular reactors that provide defined plug flow residence time for viral inactivation have been developed by several equipment suppliers and have been included in continuous manufacturing regulatory submissions, demonstrating that the viral safety requirements can be met in a continuous processing context. The regulatory pathway for continuous viral inactivation has been clarified through interactions between biopharmaceutical manufacturers and FDA and EMA in the context of continuous manufacturing regulatory submissions, reducing the regulatory uncertainty that was an earlier barrier to downstream continuous processing adoption.
Regulatory Acceptance and FDA Guidance
The regulatory acceptance of continuous bioprocessing by FDA and EMA has evolved from cautious initial engagement to active encouragement, as regulators have recognised that well-designed continuous processes with appropriate PAT-based monitoring can provide better process control and product quality consistency than batch processes where only end-of-batch testing is performed. The FDA's emerging technology program, which provides early regulatory engagement for manufacturers developing novel manufacturing approaches including continuous processing, has supported several continuous bioprocessing regulatory submissions and provided feedback that has clarified the regulatory expectations for continuous manufacturing process characterisation and control strategy development.
The first FDA approvals of biologics manufactured using continuous processing included Janssen's Prezista (darunavir, a small molecule) and several biologic products that have incorporated upstream continuous processing steps, establishing the regulatory precedent that continuous manufacturing can support approved commercial biologics processes. The accumulation of approved continuous manufacturing submissions has reduced the regulatory risk perception that was an early barrier to investment, and the FDA's draft guidance on continuous manufacturing for biologics has provided a framework for the process characterisation studies, control strategy documentation, and change management approaches that continuous process regulatory submissions require.
The European Medicines Agency has been active in developing its own regulatory framework for continuous manufacturing, participating in ICH Q13 guideline development on continuous manufacturing that provides internationally harmonised guidance applicable to both small molecule and biologic continuous manufacturing processes. The ICH Q13 guideline, finalised in 2022, provides the most authoritative international regulatory framework for continuous manufacturing and has been influential in reducing regulatory uncertainty in markets outside the US and EU where harmonised international guidance provides the most practical reference for manufacturers and regulators alike.
Economic Case and Industry Adoption
The economic case for continuous bioprocessing is most compelling in specific scenarios: manufacturing facilities where capital cost reduction through smaller equipment footprint is a priority, cell therapy and personalised medicine manufacturing where the small batch sizes of patient-specific products are better served by continuous small-scale processing than by scaled batch equipment, and next-generation manufacturing facilities being designed from the ground up where continuous processing can be incorporated into the facility design rather than retrofitted into batch-era infrastructure. Roche, Sanofi, AstraZeneca, and several contract development and manufacturing organisations including Lonza and Samsung Biologics have announced continuous manufacturing programs at varying stages of implementation, reflecting broad industry recognition of the direction of manufacturing technology development.
The capital cost reduction potential of continuous bioprocessing stems from the ability to achieve the same annual production volume with smaller bioreactors operating continuously at high cell density than with larger bioreactors operating in fed-batch mode. A perfusion bioreactor of 2,000 litres operating continuously can produce comparable annual product mass to a fed-batch bioreactor of 10,000 to 20,000 litres, reducing the capital cost of the bioreactor and associated downstream equipment while also reducing the facility footprint, cleaning-in-place and sterilisation-in-place requirements, and labour required for batch changeover operations. The capital cost saving is not fully realised in retrofits of existing batch facilities where the downstream equipment capacity must still accommodate the continuous upstream output, making new facility design the context where the full economic case is most readily demonstrated.
Top 10 Companies in Continuous Bioprocessing Technology
- Sartorius -- German bioprocess equipment company with perfusion bioreactors, cell retention systems, and downstream processing equipment supporting continuous bioprocessing implementation at development and commercial scale
- Cytiva -- Danaher life sciences company with BioSMB continuous chromatography, WAVE and other bioreactor platforms, and comprehensive single-use continuous bioprocessing product portfolio
- Merck KGaA -- German pharmaceutical and life sciences company with MilliporeSigma bioprocess equipment and consumables for continuous upstream and downstream processing, alongside its own biologics manufacturing programs
- Pall Corporation -- Danaher filtration company with continuous downstream processing systems including alternating tangential flow filtration and continuous chromatography products for biopharmaceutical manufacturing
- Lonza -- Swiss CDMO with active continuous bioprocessing capability development for client biologic manufacturing programs, investing in continuous technology to offer faster and more cost-effective manufacturing services
- Roche -- Swiss biopharmaceutical company with significant continuous bioprocessing investment in its manufacturing network, applying continuous technology to its monoclonal antibody production programs
- Sanofi -- French pharmaceutical company with continuous manufacturing programs across biologics and vaccines, applying continuous processing to improve manufacturing flexibility and reduce production costs
- Samsung Biologics -- Korean contract biologic manufacturer with investment in continuous processing capability to differentiate its CDMO service offering and reduce manufacturing cost for client programs
- AstraZeneca -- UK-Swedish biopharmaceutical company with continuous manufacturing initiatives in its biologics pipeline, applying continuous processing to improve facility efficiency and manufacturing agility
- Novatek International -- Bioprocess technology company commercialising MCSGP multicolumn chromatography for continuous downstream biologics purification, with installations at commercial biopharmaceutical manufacturers